Haleon Share Discussion Threads

[drew lonmenob] 18/8/2022 09:40

its the same analogy idiot

[medieval blacksmith] 18/8/2022 09:38

Doesn't excess stomach acid increase your chances of oesophageal cancer? I would have thought that someone suffering from regular heartburn would more likely also have issues with diet and obesity both of which can increase chances of cancers.

[medieval blacksmith] 18/8/2022 09:33

I didn't say that Drew. You have a very simplistic brain.

Can I call you Mr Black & White?

[drew lonmenob] 18/8/2022 09:25

so prince andrew is innocent then is he ?

[medieval blacksmith] 18/8/2022 09:17

They pay it because continuing legal issues would cost more. Paying is not admittance of guilt.

[paul planet_earth] 18/8/2022 07:09

Dead Man Walking!

Vultures are circling!

[paul planet_earth] 18/8/2022 06:52

So much for all these denials with the first plaintiff receiving a $500k pay off...Just another 1,999 to go in the first of many, many, class law suits now in the pipeline..

Question if your innocent why pay a dime!..

'Bloomberg reported that generic drugmakers Teva, Perrigo, Sun Pharma and Dr Reddy's Laboratories agreed to a combined settlement of more than $500,000 with the claimant after he alleged Zantac, a medication for heartburn, caused his oesophageal cancer. Haleon, the former consumer healthcare joint venture of GSK and Pfizer, has said it is not a party to any Zantac claims and conditions would need to be met before it was required to indemnify GSK and Pfizer of any liabilities,'

Talk about a bunch of blatant liars and double standards claiming publicly they are innocent but willing to pay out hush money to plaintiffs to drop their claims and besides the first plaintiff was very ill and in hospital following an operation, ffs, what are these pharma companies thinking!

[unastubbs] 18/8/2022 05:55

this in The Times today offers some insight in to the story yesterday about the first case being withdrawn

"Shares in Haleon fell to fresh lows and GSK, which spun the company off last month, weakened over concerns about potential liabilities relating to Zantac after a report that generic drug companies had reached a settlement in a US legal case (Alex Ralph writes). It emerged on Tuesday that the plaintiff in the first lawsuit due to go to trial in Illinois had dropped his case. GSK, a defendant in the case, welcomed the decision. A lawyer for the claimant, however, said her client had decided not to pursue the case at this time because of complications from the removal of his oesophagus. Bloomberg reported that generic drugmakers Teva, Perrigo, Sun Pharma and Dr Reddy's Laboratories agreed to a combined settlement of more than $500,000 with the claimant after he alleged Zantac, a medication for heartburn, caused his oesophageal cancer. Haleon, the former consumer healthcare joint venture of GSK and Pfizer, has said it is not a party to any Zantac claims and conditions would need to be met before it was required to indemnify GSK and Pfizer of any liabilities. Haleon closed down 10¾p at 258½p and GSK fell 9½p to £14.15½p."

[philanderer] 17/8/2022 21:56

Not quite up to speed on this as away on holiday but just read this..

"...If held liable in any case, GSK has said it has served Haleon with notice that it may try to recover payments from the company. "

[paul planet_earth] 17/8/2022 20:33

HALEON PLC
LON: HLN
OverviewNewsCompareFinancials
257.10 GBX -51.25 (-16.62%)past month
17 Aug, 17:11 BST • Disclaimer

Now below £23 billion take over target!

[paul planet_earth] 17/8/2022 15:26

From £50.5 billion to under £23 billion within six months!

[paul planet_earth] 17/8/2022 15:24

HALEON PLC
LON: HLN
OverviewNewsCompareFinancials
258.20 GBX -50.15 (-16.26%)past month
17 Aug, 16:22 BST • Disclaimer

[paul planet_earth] 17/8/2022 06:48

Haleon now worth less than half what Unilver offered says it all...dead man walking!

[unastubbs] 17/8/2022 05:56

From The Times Market Report today:

"To take a punt on Haleon or not? That has been the question on many investors’ lips since the owner of brands such as Sensodyne and ChapStick was spun out of GSK last month.

"Analysts at RBC, the Canadian investment bank, had been getting ready to tell their clients to buy Haleon shares, but decided against it yesterday, telling them to hold fire instead. While acknowledging that Haleon had “some exceptional brands”, such as Sensodyne, Voltarol and Centrum, upon closer inspection most of the brand portfolio was merely “adequate̶1;.

“We’re less overawed by the Haleon business than we had expected to be. Too many of [its brands] are runners-up in their respective categories in our opinion,” they concluded. The biggest “turn-off̶1;, though, was the potential for a costly legal wrangle over Zantac — GSK’s once all-conquering stomach ulcer drug that recently has been linked to cancer. “We’re not lawyers, but we’re pretty sure that this sort of potential litigation liability isn’t the reason that investors buy consumer staples shares,” the RBC analysts said.

"Given that, RBC thinks the shares are now fairly valued, having dived by a fifth in over the past month. The stock nudged up 2½p, or 0.9 per cent, to 269p yesterday — still some way shy of the 330p at which they made their debut in July."

[paul planet_earth] 17/8/2022 05:29

Hardly the plaintiff is seriously ill and unable to pursue the matter in court at this point due to health issues but retains the right to expedite the legal action within a year..FFS the guys in hospital long term sick and can't make a court appearance and GSK calls this a victory and decisive win!..Only another 1,999 cases out of the 2,000 plaintiffs lodged and pending trial in September well that's a relief!!.

[paul planet_earth] 16/8/2022 21:23

Good Luck you will need it companies always deny accusations otherwise they would be paying out hand over fist so I don't read much into what GSK state..They are hardly going to put their hands in the air and admit liability!

'Bloomberg reported that generic drugmakers Teva, Perrigo, Sun Pharma and Dr Reddy's Laboratories agreed to a combined settlement of more than $500,000 with the claimant after he alleged Zantac, a medication for heartburn, caused his oesophageal cancer. Haleon, the former consumer healthcare joint venture of GSK and Pfizer, has said it is not a party to any Zantac claims and conditions would need to be met before it was required to indemnify GSK and Pfizer of any liabilities'

[dr biotech] 16/8/2022 20:07

FWIW Drug watch is a website that is largely funded by lawfirms looking to fie lawsuits against drug manufacturers. So not exactly a neutral perspective.

[dr biotech] 16/8/2022 19:57

Alliance News) - GSK PLC said on Tuesday the first scheduled trial in its Zantac case has been voluntarily dismissed.

GSK, among others, has come under pressure that heartburn treatment Zantac causes cancer. Its consumer healthcare spin-off Haleon PLC is implicated, as is French firm Sanofi SA and US firm Pfizer Inc.

The pharma firm noted it did not pay anything in exchange for the voluntary dismissal.

"GSK welcomes this outcome and believes the dismissal of Joseph Bayer's case is the correct result. The overwhelming weight of the scientific evidence supports the conclusion that there is no increased cancer risk associated with the use of ranitidine. GSK will continue to vigorously defend itself against all claims alleging otherwise," it added.

Moving forward, GSK noted cases where it is named, a trial in California is currently scheduled to begin February 13 and a trial is currently scheduled to begin in Madison County, Illinois in February 2023.

Zantac was withdrawn after the US Food & Drug Administration in 2019 warned that the product contained levels of NDMA, a probable human carcinogen - a substance which has been linked to cancer.

While the worries were not new, it particularly grabbed investor attention last week. In its listing prospectus, Haleon actually mentioned Zantac litigation. It noted GSK and Pfizer, its former owners, were named as a defendant in roughly 2,150 US "personal injury lawsuits involving Zantac".

On Tuesday, GSK put this number at about 3,000.

Haleon on Thursday said it was not aware of any material developments in relation to Zantac since the start of June. The spin-off of Haleon from GSK was completed in mid-July; the consumer healthcare business previously had been run as a joint venture with Pfizer, which owned just under a third.

Haleon said that it is "not primarily liable" for any over-the-counter or prescription claims involving Zantac.

However, it cautioned it may need to eventually compensate both GSK and Pfizer should the duo come into the legal cross-hairs.

Pfizer sold Zantac products between 1998 and 2006. By the time there was a withdrawal of Zantac products from the market in 2019 and 2020, Pfizer had already stopped selling it.

Ranitidine, sold under the brand Zantac, was originally manufactured by GSK, and French pharmaceutical firm Sanofi bought the rights to branded over-the-counter US sales back in 2017.

In a statement on Tuesday, GSK said US and European regulators have undertaken "extensive" reviews of the drug since it was taken off the shelves in 2019.

"Based on these investigations and experiments, GSK, the FDA, and the EMA have all independently concluded that there is no evidence of a causal association between ranitidine therapy and the development of cancer in patients," it said.

GSK added: "Since the issue concerning the presence of NDMA in ranitidine arose in 2019, the scientific community has actively focused on understanding whether there is a link between ranitidine and cancer. There have been 11 epidemiological studies conducted in that time looking at human data regarding the use of ranitidine, with the resulting scientific consensus, that the totality of the reliable evidence does not support that ranitidine increases the risk of any type of cancer."

Shares in GSK closed 1.4% higher in London on Tuesday at 1,425.75 pence. Haleon gained 0.1% to 266.98p, while Sanofi added 1.7% in Paris to EUR86.59. Pfizer was up 0.2% in New York at USD49.87.

[paul planet_earth] 16/8/2022 18:27

Dr Biotech.

Wrong the courts will look at actual recorded evidence and research which forms the pretext for legal action. Wishful thinking and waffle won't hold water and what you are conveying with your conspiracy theories mean Jack squat at the end of the day!

[paul planet_earth] 16/8/2022 18:21

Does Zantac Cause Cancer?

Zantac contaminated with NDMA, a cancer-causing chemical, has been linked to cancer. Types of cancer caused by Zantac include bladder cancer, colon cancer and prostate cancer. In April 2020, Zantac products were withdrawn from the market because of the potential cancer

So far, there are over 500 federal Zantac lawsuits filed in Florida federal court against the makers of the anti-acid drug. These lawsuits claim Zantac caused several types of cancer and drug makers failed to warn the public.

Unfortunately, the science regarding Zantac made with ranitidine and cancer in humans hasn’t shown a definitive answer.

Concerns over Zantac’s link to cancer stem from a potential connection between ranitidine and its ability to form NDMA. Some studies as far back as the 1980s hinted at a link between the drug and NDMA formation. But one study that looked at the records of 65 million people found people who took ranitidine had less of a cancer risk than those who took another H2 blocker, famotidine.

Since the FDA requested a market withdrawal of all Zantac products containing ranitidine, Sanofi released a new Zantac 360 over-the-counter formula made with famotidine. So far, the FDA hasn’t linked famotidine to NDMA contamination or an increased risk of cancer.

[dr biotech] 16/8/2022 15:11

Difference between Zantac and Roundup is that the stats were able to produce a probable link between glyphosate and a specific cancer, Non-Hodgkins lymphoma. As far as I am aware there is no link between Zantac and any specific tumour type. In fact certain types of cancer are reduced.


We’ll have to see what evidence will be given. We’re in a post truth world where saying things without evidence (ie antivax) gets a lot of traction with some of the public but hasn’t yet taken over the law courts. Having a very Ill patient point a finger at a faceless pharma carries a lot of emotional weight. But I’d expect GSK to come out winners in the end